TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Barthel score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Major adverse cardiovascular event (MACE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: radiographic bone union rate of fibula
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SF‐36 score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: time for resolution of tenderness at the fracture site
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activities of Daily Living (ADL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arm function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate-pressure product (RPP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Myocardial carbon 11 acetate decay rate (kmono)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: oral clearance of chlorzoxazone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oral clearance of caffeine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma potassium concentration changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: endothelial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Appetite score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: T cell response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: morbidity and mortality in CRC patients
Endpoint domain: Mortality/survival
Primary endpoint: incidence of new cerebral ischemic lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: number of new cerebral ischemic lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: volume of new cerebral ischemic lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean daily intake of total vegetables
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean daily fat intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean plasma levels of carotenoids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minute Ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibition of vasoconstriction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Knee Society Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feller score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anterior knee pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical response to cardiac resynchronization therapy (CRT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24BP reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: MRproANP plasma concentration increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: incidence of sinus perforation
Endpoint domain: Adverse events/effects
Primary endpoint: apoprotein A‐I
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: apoprotein B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: apoprotein B/apoprotein A‐I ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: plasma epinephrine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: serum-free fatty acids concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: insulin resistance (homeostasis model assessment-IR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of early postoperative complications
Endpoint domain: Adverse events/effects
Primary endpoint: stool output during the first 24 hours of maintenance therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: total stool output during maintenance therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: duration of diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Frequency of individuals with antibody specific for LND
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: median fever disappearance time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: markedly effective rate of TCM symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recovery rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidences of hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Duration of hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: False hypoglycemia alarms
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of A. lumbricoides infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Intensity of A. lumbricoides infections (mean epg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Wound healing rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time to healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kidney acute rejection episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Mean pain score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood concentration of hydroxyproline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Levels of urinary pyridinoline cross-links
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 30 day-mortality
Endpoint domain: Mortality/survival
Primary endpoint: pain free grip strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subjective assessment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinical progression of NEC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of microalbuminuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Placebo response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone mineral density (BMD) accretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone turnover
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum parathyroid hormone concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in systolic blood pressure levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: discriminability (d')
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: speeded reaction times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: errors of commission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity at 4 mm threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive predictive value at 4 mm threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic confidence improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction of enamel demineralization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in CES-D scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Quality of discharge summaries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean maximum plasma paracetamol concentration (Cmax/BM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean area under plasma paracetamol concentration-time curve (AUC/BM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: family-physician communication
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: information for the family
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: involvement in care decisions
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Reduction in tooth demineralization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in remineralization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Worsening renal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Difference in ASD prescription rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of bleeding days after evacuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of vaginal bleeding lasting 10 days or more
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endometrial thickness 10 days after evacuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of calories from total fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: percentage of calories from saturated fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: nutrition knowledge improvement
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: serum SHBG concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: blood flow in lower limb vessels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Allowing children to use indoor-tanning devices
Endpoint domain: Adverse events/effects
Primary endpoint: Misinformation regarding risks of indoor tanning
Endpoint domain: Adverse events/effects
Primary endpoint: Detection of viability between PET and SPECT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: patient satisfaction regarding analgesic therapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mobility performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: muscular strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: body composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Participant-reported outcomes
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Serum ionized calcium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Parathyroid hormone (PTH) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: C-terminal telopeptide of type I collagen (CTX) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mortality risk associated with persistent symptoms of anxiety and depression
Endpoint domain: Mortality/survival
Primary endpoint: grip strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean increase in central corneal thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Density of endothelial cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in intraocular pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasminogen activator inhibitor-1 (PAI-1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mortality rate at 3 months
Endpoint domain: Mortality/survival
Primary endpoint: Days of treatment required
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: abnormal child outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tissue thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: mean intraoperative fluoroscopy time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: mean OR time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: safety and efficacy of prophylactic steroids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pressure Pain Sensitivity (PPT levels)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Albumin increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Haemoglobin increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum ferritin increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: EC50 for propofol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: site-specific intestinal ranitidine absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: satisfaction with the improved process
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total success percentage of ARTs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visuospatial memory performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: plasma kynurenine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BPRS total scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Handgrip strength in the dominant hand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fat-free mass (FFM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in N-telopeptides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Seroprevalence of HSV-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Seroprevalence of HSV-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Plasma LDL cholesterol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Frequency of blighted ova
Endpoint domain: Mortality/survival
Primary endpoint: Frequency of IUFDs
Endpoint domain: Mortality/survival
Primary endpoint: WM accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WM load-related activity in the right superior frontal gyrus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: WM load-related deactivation of the left hippocampus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Grade 3/4 toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Subjective improvement of Stress Urinary Incontinence (SUI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective improvement of Stress Urinary Incontinence (SUI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incontinence before and after operation (ICIQ questionnaire)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain scores at movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient comfort scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: complete response (no emetic episodes and no rescue for 24 hr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Suicide attempts
Endpoint domain: Mortality/survival
Primary endpoint: Area under the rivaroxaban concentration-time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative incidence of graft rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Transplant outcomes
Primary endpoint: catheterization skill performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to intubation (TTI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in LDL cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically meaningful improvement in disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improvement in pain intensity (at worst)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epithelial permeability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of inflammatory adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Risk of lens-induced adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline YMRS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for surfactant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Need for mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of air leaks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rates of optimal endotracheal tube placements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of satisfactory endotracheal tube placements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Upper limb function increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perceived personal susceptibility to infertility
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: worry about infertility
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: infertility-related knowledge
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Mortality due to liver failure
Endpoint domain: Mortality/survival
Primary endpoint: Development of RA
Endpoint domain: Mortality/survival
Primary endpoint: Genant-modified Sharp radiographic scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRI erosion, osteitis and synovitis scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days of abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days of drunkeness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bubble formation during RF ablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum OPG concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of high-grade prostate cancer (Gleason ≥ 7)
Endpoint domain: Mortality/survival
Primary endpoint: Success rate of CPAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: mean total symptoms score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in number of actinic keratoses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Cumulative fentanyl consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain intensity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of drowsiness
Endpoint domain: Adverse events/effects
Primary endpoint: Composite of cardiovascular death, myocardial infarction, stroke, or hospitalization for heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Composite of chronic dialysis or doubling of creatinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: exacerbation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FEV(1) decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Tooth extraction due to treatment plan changes
Endpoint domain: Adverse events/effects
Primary endpoint: No failures observed
Endpoint domain: Mortality/survival
Primary endpoint: Isometric and isokinetic thigh muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle cross-sectional area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes